Initiation of Ph 1/2 study of AVZO-103 in patients with advanced solid tumors announced October 8, 2025
OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates October 7, 2025
FDA clears IND application for CDH17-targeting ADC SIM0609 for the treatment of advanced solid tumors October 7, 2025
TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer September 30, 2025
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811) September 26, 2025
First patient dosed in Ph 1/2 Dose Escalation & Expansion Trial of CP-383 in Advanced Solid Tumors September 23, 2025
FDA Approves SC KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection Across Most Solid Tumor Indications for KEYTRUDA September 23, 2025
LP-184 Ph 1a Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors September 23, 2025
Enrollment of Ph 1 TRE-515 Dose Escalation Trial for Patients with Solid Tumors Completed September 16, 2025
Rezatapopt Monotherapy Interim Data From PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced September 16, 2025
Radiance Biopharma signs Exclusive License Agreement with Novatim Immune Therapeutics for RB-601™ (KY-0301), the c-MET/EGFR-targeting ADC September 10, 2025
Silexion Therapeutics Announces Selection of CRO to Support Upcoming Ph 2/3 Clinical Trials for SIL204 September 10, 2025
WCLC 2025: Interim Ph 2 Data for Pumitamig (BNT327/BMS986545) in Patients with ES-SCLC Shows Encouraging Antitumor Activity September 9, 2025
First cohort in Ph 1 trial of 177Lu-AKIR001 completed in patients with solid tumors September 3, 2025
SAKK 66/17 Ph 1b/2a Clinical Trial of IP-001 for Treatment of Solid Tumors Completed September 3, 2025
FDA INTERACT meeting completed in preparation to advance TBC-1 toward IND-enabling studies September 3, 2025
Incyclix Bio Secures $11.25M Series B Extension for Ph 1/2 Trial of INX-315 in CDK4/6i-Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors August 26, 2025
FDA IND application for ST-01156 Ph 1 trial in patients with advanced solid tumor and heme malignances August 19, 2025
